A pilot study suggests that the bispecific T cell engager blinatumomab may provide a new therapy for patients with refractory rheumatoid arthritis; larger studies and deep phenotyping will be crucial to thoroughly evaluate and optimize this approach.
This is a preview of subscription content, log in via an institution to check access.
References
Edwards, J. C. W. et al. New Engl. J. Med. 350, 2572–2581 (2004).
Buch, M. H., Eyre, S. & McGonagle, D. Nat. Rev. Rheumatol. 17, 17–33 (2021).
Bykerk, V. P. Nat. Rev. Rheumatol. 14, 191–192 (2018).
Bucci, L. et al. Nat. Med. https://doi.org/10.1038/s41591-024-02964-1 (2024).
Teng, Y. K. O. et al. Arthritis Rheum. 56, 3909–3918 (2007).
Kavanaugh, A. et al. Ann. Rheum. Dis. 67, 402–408 (2008).
Kantarjian, H. et al. New Engl. J. Med. 376, 836–847 (2017).
Topp, M. S. et al. J. Clin. Oncol. 29, 2493–2498 (2011).
Isaacs, J. D. et al. Ann. Rheum. Dis. 72, 329–336 (2013).
Rivellese, F. et al. Nat. Med. 28, 1256–1268 (2022).
Mauri, C. & Menon, M. J. Clin. Invest. 127, 772–779 (2017).
Mackensen, A. et al. Nat. Med. 28, 2124–2132 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
L.T. reports consultant or speaker fees from GSK and AbbVie; and research funding from Sanofi. B.K. reports consultant or speaker fees from Abbvie, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB. F.H. reports consultant or speaker fees from Galapagos, Roche and Abbvie.
Rights and permissions
About this article
Cite this article
Humby, F., Kirkham, B. & Taams, L. BiTE therapy for rheumatoid arthritis. Nat Med (2024). https://doi.org/10.1038/s41591-024-02982-z
Published:
DOI: https://doi.org/10.1038/s41591-024-02982-z
- Springer Nature America, Inc.